ZWJ Investment Counsel Inc. lifted its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 12.2% in the first quarter, HoldingsChannel reports. The institutional investor owned 56,800 shares of the biopharmaceutical company’s stock after buying an additional 6,185 shares during the quarter. ZWJ Investment Counsel Inc.’s holdings in Alexion Pharmaceuticals were worth $7,678,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently modified their holdings of ALXN. FMR LLC increased its holdings in shares of Alexion Pharmaceuticals by 25.1% in the 4th quarter. FMR LLC now owns 26,398,265 shares of the biopharmaceutical company’s stock valued at $2,570,135,000 after purchasing an additional 5,301,272 shares during the period. Norges Bank bought a new stake in Alexion Pharmaceuticals during the fourth quarter worth approximately $388,934,000. Artisan Partners Limited Partnership boosted its position in Alexion Pharmaceuticals by 220.9% during the first quarter. Artisan Partners Limited Partnership now owns 4,248,248 shares of the biopharmaceutical company’s stock worth $574,278,000 after purchasing an additional 2,924,550 shares during the period. Jennison Associates LLC boosted its position in Alexion Pharmaceuticals by 17.3% during the first quarter. Jennison Associates LLC now owns 10,241,457 shares of the biopharmaceutical company’s stock worth $1,384,440,000 after purchasing an additional 1,512,545 shares during the period. Finally, FIL Ltd boosted its position in Alexion Pharmaceuticals by 629.3% during the first quarter. FIL Ltd now owns 1,208,567 shares of the biopharmaceutical company’s stock worth $163,373,000 after purchasing an additional 1,042,846 shares during the period. Institutional investors and hedge funds own 94.42% of the company’s stock.
In other news, Director Bros. Advisors Lp Baker sold 123,489 shares of the firm’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $126.53, for a total transaction of $15,625,063.17. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 4.08% of the company’s stock.
Several research firms have recently weighed in on ALXN. Cowen reissued a “buy” rating and issued a $165.00 price objective on shares of Alexion Pharmaceuticals in a research report on Wednesday, March 13th. Raymond James upped their target price on Alexion Pharmaceuticals from $161.00 to $164.00 and gave the company an “outperform” rating in a research note on Friday, April 26th. Guggenheim restated a “neutral” rating and issued a $135.00 target price on shares of Alexion Pharmaceuticals in a research note on Thursday, March 21st. BidaskClub upgraded Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, March 1st. Finally, Citigroup dropped their price objective on Alexion Pharmaceuticals from $180.00 to $165.00 and set a “buy” rating for the company in a research note on Thursday, May 23rd. Seven equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $161.06.
NASDAQ ALXN opened at $117.93 on Monday. The stock has a market cap of $26.44 billion, a PE ratio of 16.63, a price-to-earnings-growth ratio of 0.88 and a beta of 1.58. The company has a current ratio of 3.87, a quick ratio of 3.36 and a debt-to-equity ratio of 0.25. Alexion Pharmaceuticals, Inc. has a one year low of $92.56 and a one year high of $141.86.
Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported $2.39 EPS for the quarter, topping the Zacks’ consensus estimate of $1.99 by $0.40. The company had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.13 billion. Alexion Pharmaceuticals had a return on equity of 19.53% and a net margin of 9.59%. Alexion Pharmaceuticals’s revenue was up 22.5% compared to the same quarter last year. During the same quarter last year, the firm posted $1.68 earnings per share. Research analysts anticipate that Alexion Pharmaceuticals, Inc. will post 8.61 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece of content was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2019/06/17/zwj-investment-counsel-inc-purchases-6185-shares-of-alexion-pharmaceuticals-inc-nasdaqalxn.html.
Alexion Pharmaceuticals Profile
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
Read More: Resistance Level
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.